Rise Therapeutics Secures Funding to Develop a Novel Immunologically-Directed Probiotic for the Treatment of Inflammatory Bowel Disease
Rise Therapeutics, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) grant to fund the development of the novel engineered probiotic for the treatment of inflammatory bowel disease (IBD).